GGrantIndex
← Leaderboards

Yvonne J Bryson

University Of California Los Angeles

Google Scholar ↗PubMed ↗ORCID ↗
$45,728,199
Attributed
$50,032,183
Total exposure
33
Grants
10
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $6.3M · FY2005–18
$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18

Funding mix

By agency

NIH$50,032,183 · 33

By mechanism

U01$33,304,782 · 3
R01$6,455,976 · 1
M01$5,172,594 · 28
UM1$5,098,831 · 1

Top collaborators

Most similar at University Of California Los Angeles

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research”

Research focus

Clinical ResearchHuman SubjectPediatric AidsHuman Therapy EvaluationHiv InfectionsAids TherapyClinical Trial Phase IPerinatalDrug Screening /EvaluationVertical TransmissionUnited States National Institutes Of HealthCombination ChemotherapyClinical TrialsInfantAdolescentChildInfant Human (0-1 Year)Aids Education /PreventionCohortAcquired Immunodeficiency SyndromeHuman Pregnant SubjectChild (0-11)BrazilAntiaids Agent

Grant awards (80)

Early Antiretroviral Therapy and HIV Remission in Perinatal Infection$1,162,650
R01 · FY2018 · HD
Early Antiretroviral Therapy and HIV Remission in Perinatal Infection$1,167,223
R01 · FY2017 · HD
Early Antiretroviral Therapy and HIV Remission in Perinatal Infection$69,945
R01 · FY2017 · HD
Early Antiretroviral Therapy and HIV Remission in Perinatal Infection$1,160,228
R01 · FY2016 · HD
Early Antiretroviral Therapy and HIV Remission in Perinatal Infection$221,705
R01 · FY2016 · HD
Early Antiretroviral Therapy and HIV Remission in Perinatal Infection$81,324
R01 · FY2016 · HD
Early Antiretroviral Therapy and HIV Remission in Perinatal Infection$1,172,270
R01 · FY2015 · HD
Early Antiretroviral Therapy and HIV Remission in Perinatal Infection$153,714
R01 · FY2015 · HD
Early Antiretroviral Therapy and HIV Remission in Perinatal Infection$1,266,917
R01 · FY2014 · HD
UCLA Los Angeles Brazil AIDS Consortium$844,094
UM1 · FY2014 · AI · contact PI
UCLA Los Angeles Brazil AIDS Consortium$2,744,657
UM1 · FY2013 · AI · contact PI
UCLA Los Angeles Brazil AIDS Consortium$1,510,080
UM1 · FY2012 · AI · contact PI
UCLA Los Angeles Brazil AIDS Consortium$2,307,974
U01 · FY2011 · AI · contact PI
UCLA Los Angeles Brazil AIDS Consortium$2,586,074
U01 · FY2010 · AI · contact PI
UCLA Los Angeles Brazil AIDS Consortium$52,204
U01 · FY2010 · AI · contact PI
CLINICAL TRIAL: PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRAL DRUGS DURING PREGNA$1,493
M01 · FY2010 · RR · contact PI
UCLA Los Angeles Brazil AIDS Consortium$3,130,868
U01 · FY2009 · AI · contact PI
UCLA Los Angeles Brazil AIDS Consortium$2,284,062
U01 · FY2008 · AI · contact PI
METHODS FOR EARLY HIV INFECTION DIAGNOSIS$1,755
M01 · FY2008 · RR · contact PI
UCLA Los Angeles Brazil AIDS Consortium$2,322,195
U01 · FY2007 · AI · contact PI
PERINATAL CORE PROTOCOL - PACTG P1025$116,204
M01 · FY2007 · RR · contact PI
PEDIATRIC LATE OUTCOMES PROTOCOL (ACTG 219C)$3,320
M01 · FY2007 · RR · contact PI
A PHASE II/III RANDOMIZED, OPEN-LABEL STUDY OF COMBINATION ANTIRETROVIRAL REG$2,215
M01 · FY2007 · RR · contact PI
BRAZILIAN AIDS PREVENTION TRIALS INTERNATIONAL NETWORK$1,820,300
U01 · FY2006 · AI · contact PI
Los Angeles Pediatric AIDS Clinical Trials Unit$777,136
U01 · FY2006 · AI · contact PI
PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRAL DRUGS DURING PREGNANCY - PACTG 1$4,167
M01 · FY2006 · RR · contact PI
BRAZILIAN AIDS PREVENTION TRIALS INTERNATIONAL NETWORK$5,201,772
U01 · FY2005 · AI
Los Angeles Pediatric AIDS Clinical Trials Unit$1,036,176
U01 · FY2005 · AI
PHASE I/II TRIAL OF CD4-IGG2 IN HIV-INFECTED CHILDREN (PACTG PROTOCOL 351 VER$5,925
M01 · FY2005 · RR
PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRAL DRUGS DURING PREGNANCY - PACTG 1$5,267
M01 · FY2005 · RR
PERINATAL CORE PROTOCOL - PACTG P1025$1,975
M01 · FY2005 · RR
BRAZILIAN AIDS PREVENTION TRIALS INTERNATIONAL NETWORK$2,692,521
U01 · FY2004 · AI
Los Angeles Pediatric AIDS Clinical Trials Unit$983,776
U01 · FY2004 · AI
METHODS FOR EARLY HIV INFECTION DIAGNOSIS$37,059
M01 · FY2004 · RR
BRAZILIAN AIDS PREVENTION TRIALS INTERNATIONAL NETWORK$4,575
U01 · FY2004 · AI
PEDIATRIC LATE OUTCOMES PROTOCOL (ACTG 219C)$3,089
M01 · FY2004 · RR
Phase I/II Study of Safety and Immunogenicity of Live-At$1,853
M01 · FY2004 · RR
Phase I/II, Open-Label, Pharmacokinetic and Safety Stu$1,236
M01 · FY2004 · RR
PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRAL DRUGS DURING PREGNANCY - PACTG 1...$617
M01 · FY2004 · RR
USE OF A LIVE-ATTENUATED VARICELLA-ZOSTER VIRUS (VZV) VACCINE TO BOOST IMMUNI...$617
M01 · FY2004 · RR
BRAZILIAN AIDS PREVENTION TRIALS INTERNATIONAL NETWORK$2,106,836
U01 · FY2003 · AI
Los Angeles Pediatric AIDS Clinical Trials Unit$1,009,613
U01 · FY2003 · AI
Los Angeles Pediatric AIDS Clinical Trials Unit$1,026,140
U01 · FY2002 · AI
BRAZILIAN AIDS PREVENTION TRIALS INTERNATIONAL NETWORK$599,397
U01 · FY2002 · AI
LOS ANGELES PEDIATRIC AIDS CONSORTIUM$1,270,551
U01 · FY2001 · AI
BRAZILIAN AIDS PREVENTION TRIALS INTERNATIONAL NETWORK$344,028
U01 · FY2001 · AI
RANDOMIZED COMPARATIVE STUDY OF COMBINED ZIDOVUDINE AND LAMIVUDINE$207,266
M01 · FY2001 · RR
PHASE I TRIAL OF SAFETY, TOLERANCE &PHARMACOKINETICS OF ORAL NELFINAVIR$207,266
M01 · FY2001 · RR
ANTIVIRAL ACTIVITY OF DMP 266 W/ NELFINAVIR IN CHILDREN$207,266
M01 · FY2001 · RR
ANTIVIRAL ACTIVITY OF DMP 266 W/ NELFINAVIR IN CHILDREN$207,266
M01 · FY2001 · RR
SAFETY &IMMUNOGENICITY OF SEVEN VALENT PNEUMOCOCCAL VACCINE IN HIV CHILDREN$207,266
M01 · FY2001 · RR
ZDV &3TC NEVIRAPINE COMBINATION THERAPY IN HIV 1 INFECTED INFANTS &$207,266
M01 · FY2001 · RR
INCREASED CALORIC DENSITY INFANT FORMULA &ITS EFFECTS$207,266
M01 · FY2001 · RR
NEVIRAPINE VS. PLACEBO TO PREVENT MATERNAL FETAL TRANSMISSION OF AIDS$207,266
M01 · FY2001 · RR
NEVIRAPINE VS. PLACEBO TO PREVENT MATERNAL FETAL TRANSMISSION OF AIDS$207,266
M01 · FY2001 · RR
SINGLE DOSE AND TWO DOSEMEASLES VACCINATION IN CHILDREN WITH OR WITHOUT HIV$207,266
M01 · FY2001 · RR
SINGLE DOSE AND TWO DOSEMEASLES VACCINATION IN CHILDREN WITH OR WITHOUT HIV$207,266
M01 · FY2001 · RR
PHASE I STUDY OF VIRACEPT IN HIV INFECTED CHILDREN$207,266
M01 · FY2001 · RR
PEDIATRIC LATE OUTCOMES PROTOCOL$207,266
M01 · FY2001 · RR
PEDIATRIC LATE OUTCOMES PROTOCOL$207,266
M01 · FY2001 · RR
HIV IMMUNOGLOBULIN IN PREGNANT WOMEN &NEWBORNS IN PREVENTING TRANSMISSION$207,266
M01 · FY2001 · RR
METHOD FOR EARLY HIV INFECTION DIAGNOSIS$207,266
M01 · FY2001 · RR
METHOD FOR EARLY HIV INFECTION DIAGNOSIS$207,266
M01 · FY2001 · RR
PHASE I TRIAL OF SAFETY, TOLERANCE &PHARMACOKINETICS OF ORAL NELFINAVIR$207,266
M01 · FY2001 · RR
TRIAL OF 1592U89 WITH ZDV IN NEONATES OF HIV MOTHERS$0
M01 · FY2001 · RR
PHASE I/II STUDY OF ALVAC HIV VACCINE ALONE/INCOMBO IN CHILD OF HIV MOTHER$0
M01 · FY2001 · RR
LOS ANGELES PEDIATRIC AIDS CONSORTIUM$1,248,584
U01 · FY2000 · AI
BRAZILIAN AIDS PREVENTION TRIALS INTERNATIONAL NETWORK$500,000
U01 · FY2000 · AI
SAFETY &IMMUNOGENICITY OF SEVEN VALENT PNEUMOCOCCAL VACCINE IN HIV CHILDREN$207,266
M01 · FY2000 · RR
HIV IMMUNOGLOBULIN IN PREGNANT WOMEN &NEWBORNS IN PREVENTING TRANSMISSION$207,266
M01 · FY2000 · RR
RANDOMIZED COMPARATIVE STUDY OF COMBINED ZIDOVUDINE AND LAMIVUDINE$207,266
M01 · FY2000 · RR
ZDV &3TC NEVIRAPINE COMBINATION THERAPY IN HIV 1 INFECTED INFANTS &$207,266
M01 · FY2000 · RR
INCREASED CALORIC DENSITY INFANT FORMULA &ITS EFFECTS$207,266
M01 · FY2000 · RR
PHASE I STUDY OF VIRACEPT IN HIV INFECTED CHILDREN$207,266
M01 · FY2000 · RR
PHASE I STUDY OF VIRACEPT IN HIV INFECTED CHILDREN$1,903
M01 · FY2000 · RR
ZDV &3TC NEVIRAPINE COMBINATION THERAPY IN HIV 1 INFECTED INFANTS &$1,903
M01 · FY2000 · RR
INCREASED CALORIC DENSITY INFANT FORMULA &ITS EFFECTS$1,903
M01 · FY2000 · RR
HIV IMMUNOGLOBULIN IN PREGNANT WOMEN &NEWBORNS IN PREVENTING TRANSMISSION$1,903
M01 · FY2000 · RR
RANDOMIZED COMPARATIVE STUDY OF COMBINED ZIDOVUDINE AND LAMIVUDINE$1,903
M01 · FY2000 · RR
SAFETY &IMMUNOGENICITY OF SEVEN VALENT PNEUMOCOCCAL VACCINE IN HIV CHILDREN$1,903
M01 · FY2000 · RR